These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21487835)

  • 1. Natalizumab and HSV meningitis.
    Shenoy ES; Mylonakis E; Hurtado RM; Venna N
    J Neurovirol; 2011 Jun; 17(3):288-90. PubMed ID: 21487835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
    Drugs R D; 2004; 5(2):102-7. PubMed ID: 15293871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients.
    Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
    Clin Infect Dis; 2013 Sep; 57(6):849-52. PubMed ID: 23728144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease.
    Ma C; Walters B; Fedorak RN
    World J Gastroenterol; 2013 Jun; 19(21):3347-51. PubMed ID: 23745038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab for the treatment of Crohn's disease.
    Bickston SJ; Muniyappa K
    Expert Rev Clin Immunol; 2010 Jul; 6(4):513-9. PubMed ID: 20594122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP
    Neurologist; 2007 Jul; 13(4):182-7. PubMed ID: 17622909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.
    Sørensen PS; Jensen PE; Haghikia A; Lundkvist M; Vedeler C; Sellebjerg F; Koch-Henriksen N; Fogdell-Hahn A; Myhr KM; Hillert J; Gold R
    Mult Scler; 2011 Sep; 17(9):1074-8. PubMed ID: 21511692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH; Bressler B
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.
    Yeung J; Cauquil C; Saliou G; Nasser G; Rostomashvili S; Adams D; Théaudin M
    Neurology; 2013 May; 80(19):1812-3. PubMed ID: 23616161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab.
    Ghosh S
    Expert Opin Biol Ther; 2003 Sep; 3(6):995-1000. PubMed ID: 12943458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
    Kohlmann R; Salmen A; Chan A; Knabbe C; Diekmann J; Brockmeyer N; Skaletz-Rorowski A; Michalik C; Gold R; Überla K
    Mult Scler; 2015 Dec; 21(14):1823-32. PubMed ID: 25828755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.
    Langer-Gould A; Steinman L
    Curr Neurol Neurosci Rep; 2006 May; 6(3):253-8. PubMed ID: 16635435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Chen Y; Bord E; Tompkins T; Miller J; Tan CS; Kinkel RP; Stein MC; Viscidi RP; Ngo LH; Koralnik IJ
    N Engl J Med; 2009 Sep; 361(11):1067-74. PubMed ID: 19741227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis.
    Nakamura M; Itani K; Miyake K; Kunieda T; Kaneko S; Kusaka H
    Intern Med; 2017; 56(2):211-214. PubMed ID: 28090055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. alpha4-Integrin antagonism with natalizumab: effects and adverse effects.
    Stüve O; Gold R; Chan A; Mix E; Zettl U; Kieseier BC
    J Neurol; 2008 Dec; 255 Suppl 6():58-65. PubMed ID: 19300961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
    Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4.
    Pauls E; Ballana E; Moncunill G; Bofill M; Clotet B; Ramo-Tello C; Esté JA
    AIDS; 2009 Jan; 23(2):266-8. PubMed ID: 19112691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.